Brought to you by 
FOPO nets $12.4mm for Synthetic Biologics
17 Dec 2013
Executive Summary
Just days after gaining IP from Cedars-Sinai Medical Center relating to archaea-implicated diseases, Synthetic Biologics Inc. (primary focus is on infectious diseases) netted $12.4mm through the follow-on public sale of 13.2mm common shares (including the overallotment) at $1.00 each.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FOPO nets $12.4mm for Synthetic Biologics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice